短期抗凝治疗与经导管主动脉瓣亚临床瓣叶增厚:NOTION-4试验
NOTION-4随机对照试验纳入无口服抗凝指征的TAVR术后患者,比较终身单抗血小板治疗(SAPT)与3个月直接口服抗凝药后转为终身SAPT(DOAC-3m)对HALT的影响。结果显示DOAC-3m在3个月时显著降低HALT发生率(12.1% vs 31.8%),但1年时差异无统计学意义(28.3% vs 32.2%,P=0.54);12个月复合终点(全因死亡、卒中或大/危及生命出血)DOAC-3m组高于SAPT组(8.2% vs 2.3%)。
要点
- TAVR术后无抗凝指征者,3个月DOAC治疗可降低3个月HALT发生率。
- 停用DOAC后9个月,HALT获益被削弱,1年时两组无显著差异。
- DOAC-3m组12个月复合临床终点风险高于SAPT组。
核心结论
- 在无口服抗凝指征的TAVR患者中,3个月DOAC治疗较SAPT显著降低3个月HALT患病率,但停药后9个月该效应减弱,1年时HALT患病率无显著差异。
研究设计与样本
- NOTION-4为随机对照试验,纳入TAVR成功术后无口服抗凝指征的患者,1:1随机分配至终身SAPT组或DOAC-3m组(3个月DOAC后终身SAPT)。
- 352例患者随机,5例筛查失败或撤回知情同意,最终SAPT组176例、DOAC-3m组171例;主要终点为12个月时HALT患病率,试验把握度基于实验策略优效性设计。
主要发现
- 3个月时HALT在SAPT组为31.8%,DOAC-3m组为12.1%。
- 1年时HALT在SAPT组为32.2%,DOAC-3m组为28.3%(有可用CT扫描者;风险差-3.9%;95%CI:-14.4%至6.6%;P=0.54)。
- 12个月全因死亡、卒中或大/危及生命出血复合风险SAPT组为2.3%,DOAC-3m组为8.2%(风险差5.9%;95%CI:1.2%至10.6%)。
临床怎么用
- TAVR术后无口服抗凝指征者,短期DOAC可减少3个月HALT,但需权衡12个月复合临床终点风险增加。
- 停用DOAC后HALT获益减弱,提示需关注停药后影像随访与个体化抗栓策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Following transcatheter aortic valve replacement (TAVR), subclinical leaflet thrombosis-visualized on cardiac computed tomography (CT) as hypoattenuated leaflet thickening (HALT)-is common and might be associated with thromboembolic events. OBJECTIVES: The NOTION-4 trial investigates different antithrombotic treatment strategies for the prevention of HALT. METHODS: NOTION-4 was a randomized controlled trial enrolling patients without an indication for oral anticoagulation shortly after successful TAVR. Patients were randomized to lifelong single antiplatelet therapy (SAPT) or 3 months of direct oral anticoagulant (DOAC) therapy followed by lifelong SAPT (DOAC-3m). The primary endpoint was HALT prevalence at 12 months. The trial was powered for superiority of the experimental strategy. RESULTS: Of 352 patients randomized 1:1, 5 were screen failures or withdrew consent, leaving 176 in the SAPT group and 171 in the DOAC-3m group. At 3 months, HALT was observed in 31.8% of patients receiving SAPT compared with 12.1% of those receiving DOAC-3m. At 1 year, HALT occurred in 32.2% of SAPT patients and 28.3% of DOAC-3m patients with available CT scans (risk difference: -3.9%; 95% CI: -14.4% to 6.6%; P = 0.54). The combined risk of all-cause mortality, stroke, or major/life-threatening bleeding at 12 months was 2.3% in the SAPT group vs 8.2% in the DOAC-3m group (risk difference: 5.9%; 95% CI: 1.2% to 10.6%). CONCLUSIONS: Among TAVR patients without an indication for oral anticoagulation, 3 months of DOAC therapy significantly reduced the prevalence of HALT at 3 months compared with SAPT; however, this effect was attenuated by 9 months after discontinuation of DOAC therapy. (The Nordic Aortic Valve Intervention Trial 4 [NOTION-4]; NCT06449469).
引用
- Jørgensen TH, Larsen AF, Jensen JM, et al. Short-Term Anticoagulant Therapy and Subclinical Leaflet Thickening in Transcatheter Aortic Valves: The NOTION-4 Trial. J Am Coll Cardiol. 2026. PMID: 42669071. doi:10.1016/j.jacc.2026.08.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。